|
|
|
|
|
|
|
|
|
12.08.25 - 07:03
|
Corporate News: Newron Pharmaceuticals S.p.A. (EQS)
|
|
|
Newron beginnt Rekrutierung für zulassungsrelevantes Phase-III-Entwicklungsprogramm ENIGMA-TRS mit Evenamide als Zusatztherapie bei Patienten mit behandlungsresistenter Schizophrenie (TRS)...
|
|
|
|
|
|
|
|
|
|
|
|
|
05.08.25 - 12:36
|
Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025 (Business Wire)
|
|
|
Company delivers 8% revenue growth, expanded margins, and maintains fiscal year 2025 guidancePIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2025.
Second Quarter 2025 Highlights (comparisons to prior-year period)
Revenue increased 8% to €280.0 million, and high-value solutions represented 42% of total revenue.
Gross profit margin increased 210 basis points to 28.1%.
Diluted earnings per share were €0.11; adjusted diluted earnings per share were €0.11.
Adjusted EBITDA margin increased 240 basis points to 23.2%.
The Company is maintaining its fiscal 2025 guidance, and continues to expect revenue in the range of €1.160 billion to €1.190 billion, adjusted EBITDA in the range of €288.5 million to €301.8 million, and adjusted diluted EPS in the range of ?...
|
|
|
|
|
|
|
30.07.25 - 13:03
|
Amarin Reports Second Quarter 2025 Financial Results (GlobeNewswire EN)
|
|
|
-- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months -- -- Q2 2025 Financial Performance Reflects Incremental Progress for VASCEPA®/VAZKEPA® in Ex-U.S. Markets, and Continued Stability in U.S. Market --...
|
|
|
29.07.25 - 18:15
|
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES IN THE FIRST HALF OF 2025 REVENUE +11.7%, EBITDA(1) +9.6%, ADJUSTED NET INCOME(2) +8.9% (GlobeNewswire EN)
|
|
|
Milan, 29th July 2025 – The Board of Directors of Recordati S.p.A. approved the interim financial statements as of June 30, 2025, pursuant to Art. 154-ter of Italian Legislative Decree 58/1998 and subsequent amendments, prepared in accordance with said Decree and the CONSOB Issuers Regulation. The statements were prepared in accordance with International Accounting Standard (IAS) 34 requirements for interim reporting, based on the assessment, measurement and recognition criteria set by the IFRSs. The interim financial statements on June 30, 2025 – as well as the Independent Auditors' report on such statements - will be available within the legal deadline at the company's offices and on the company's website (www.recordati.com) and can also be viewed on the authorized storage system 1Info(www.1Info.it)....
|
|
|
|
|
|
|
23.07.25 - 12:36
|
Stevanato Group Secures €200 Million in Financing from BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM to Fund Ongoing CAPEX Investments in Italy and the U.S. (Business Wire)
|
|
|
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it has secured €200 million in financing through agreements with BNL BNP Paribas, Cassa Depositi e Prestiti (CDP), and Banco BPM. These fundings are intended to support the Company's ongoing capital expenditure projects in Cisterna di Latina (Italy) and Fishers (Indiana, U.S.).
The financing agreements bolster Stevanato Group's capacity expansion efforts and the scaling of commercial production to support customers' growing biologics programs. CDP has committed €50 million to enhance the production of pre-filled syringes and set-up future capacity for ready-to-use (RTU) cartridges at Stevanato Group's Italian plant in Cisterna di Latina. Additionally, BNL BNP Paribas has provided €100 million, and Banco BPM has contributed €50 million, both aimed at scal...
|
|
|
22.07.25 - 22:33
|
Stevanato Group to Report Second Quarter 2025 Financial Results on August 5, 2025 (Business Wire)
|
|
|
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2025 on Tuesday, August 5, 2025, at 6:30 a.m. (ET).
Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, August 5, 2025, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the “Financial Results” page under the Company's Investor Relations section of its website.
Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. We encourage participants to pre-register for the conference call using the following link: STVN conference call pre-regi...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
